Related Experiment Video
Updated: Jul 18, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Oral therapies for diabetic hyperglycemia
1Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA.
Endocrinology and Metabolism Clinics of North America
|December 1, 2001
Summary
Combining oral antihyperglycemic agents with different mechanisms is key for managing type 2 diabetes. Combination therapy, starting with low doses, helps achieve and sustain glycemic control as the condition progresses.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Type 2 diabetes mellitus (T2DM) management often requires multiple interventions.
- Oral antihyperglycemic agents (OAAs) offer diverse mechanisms to improve glucose metabolism.
- Monotherapy with lifestyle modification or a single OAA frequently fails to achieve sustained glycemic control.
Purpose of the Study:
- To evaluate the rationale and approach for combination therapy in T2DM.
- To explore strategies for optimizing glycemic control in progressive T2DM.
Main Methods:
- Review of existing literature on OAA mechanisms and combination therapies.
- Analysis of additive effects and synergistic potential of different OAA classes.
- Consideration of patient-specific factors and disease progression in treatment selection.
Main Results:
- OAAs act via distinct pathways, offering additive benefits in combination.
- Progressive T2DM necessitates escalating therapy, including higher doses and additional agents.
- Combination therapy with agents having different mechanisms is a rational approach to sustained glycemic control.
Conclusions:
- Combination therapy is superior to monotherapy for achieving and maintaining glycemic targets in T2DM.
- Treatment strategies should adapt to disease progression, incorporating multiple OAAs or insulin as needed.
- Careful selection of OAA combinations, considering individual effects on glucose metabolism, is crucial for effective T2DM management.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...